Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 14

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 14
---
31, 2024: (i) the issuance of 2,603,652       
 Ordinary Shares upon the automatic conversion of the 2,603,652 Preferred Shares issued and outstanding as of the date hereof, which     
 will automatically convert upon the completion of this offering at a 1:1 ratio; (ii) the issuance of 609,888 Ordinary Shares upon       
 the automatic conversion of the $900,000 outstanding principal of the 2020 CLAs, which will occur upon the completion of this offering; 
 (iii) the issuance of 553,640 Ordinary Shares upon the automatic conversion of the $450,000 outstanding principal of the 2024 CLAs,     
 which will occur upon the completion of this offering; (iv) the receipt of an additional $100,000 under the Bridge Loan subsequent      
 to December 31, 2024; (v) the receipt of a loan in the total amount of $200,000 pursuant to the 2025 Loan Agreements; and (iv) the      
 expiration of certain outstanding warrants to purchase up to 167,365 Ordinary Shares in March 2025.                                     |

| (2) | The Pro Forma As Adjusted data gives additional effect to: (i) the sale                                                             
 of  1,000,000 Ordinary Shares in this offering at an initial public offering price of $11.00 per Ordinary Share,                    
 which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and 
 commissions and estimated offering expenses payable by us; (ii) repayment of the Bridge Loan in the total amount of $350,000 plus   
 accrued interest and an aggregate risk premium in the amount of $105,000; (iii) the repayment of the loan under the 2024 Loan       
 Agreements in the total amount of $150,000 plus accrued interest and an aggregate risk premium in the amount of $50,000; (iv) the   
 repayment of loan under the December 2024 Loan Agreement in the total amount of $117,000 plus value added tax, or VAT, plus accrued 
 interest and an aggregate risk premium of approximately $35,100  plus VAT; (v) the repayment of the loan under the 2025 Loan        
 Agreements in the total amount of $200,000 plus accrued interest and an aggregate risk premium in the amount of $100,000; and (vi)  
 total payment of $430,000 to CSL Beh